Director's Dealing

4Basebio

03/03/2025 16:37

3 March 2025

4basebio plc

(“4basebio” or the "Company")
 

Director’s Dealing

3 March 2025 – 4basebio PLC (AIM: 4BB), which develops and commercialises the large-scale manufacture of synthetic DNA as well as nanoparticle delivery solutions, announces that it was informed on 28 February 2025 by Dr. Amy Walker, COO of the Company, that on the same day, she acquired ordinary shares in the Company through the market, at a price of 1,120p as follows: 

Name
Numberof Shares Acquired
Shareholding Prior to the Acquisition
Shareholding Following the Acquisition
Enlarged Shareholding as a Percentage of Issued Share Capital
Dr. Amy Walker
1,151
42,865*
44,016
0.28%

* Dr Walker’s shareholding includes 2,818 ordinary shares that had been omitted in the announcement of 8 August 2024

The issued share capital of the Company comprises 15,477,395 ordinary shares.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 as amended by regulation 11 of the market abuse (amendment) (EU Exit) regulations 2019/310.

Enquiries

4basebio PLC
Dr. Heikki Lanckriet
+44 (0)1223 967 943
Nominated Adviser
Cairn Financial Advisers LLP
Jo Turner / Sandy Jamieson / Ed Downes
+44 (0)20 7213 0880
Joint Corporate Broker
RBC Capital Markets
Rupert Walford / Kathryn Deegan
+44 (0)20 7653 4000
Joint Corporate Broker
Cavendish Capital Markets Limited
Geoff Nash / Nigel Birks
+44 (0)20 7220 0500

Notes to Editors

About 4basebio

4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused on accelerating the development of advanced therapy medicinal products (ATMPs) through its high-performance synthetic DNA products and non-viral, cell targeting nucleic acid delivery platform. The Company’s objective is to become a market leader in the manufacture and supply of high-quality synthetic DNA products for research, therapeutic and pharmacological use as well as development of target specific non-viral vectors for the efficient delivery of payloads in patients.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1
Details of the person discharging managerial responsibilities/person closely associated
a.
Name
Amy Walker
2
Reason for notification
a.
Position/Status
COO
b.
Initial notification/Amendment
Initial Notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.
Name
4basebio plc
b.
LEI
213800E2DX9EAIUNCB30
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.
Description of the financial instrument, type of instrument

 Identification Code
Ordinary Shares

ISIN: GB00BMCLYF79
b.
Nature of the transaction
Acquisition of ordinary shares
Price(s) per share (p)
Volume(s)
1,120p
1,151
d.
Aggregated informationVolume
Price
1,151
1,120 pence per share
e.
Date of the transaction
28/02/2025
f.
Place of the transaction
London Stock Exchange, AIM